Gradual adalimumab tapering minimizes uveitis recurrence in children
In children with noninfectious uveitis being treated with adalimumab, tapering speed appears to affect the risk of relapse, with a slow, gradual approach emerging as the optimal strategy, according to a multicentre retrospective cohort study.
